Date: 2016-02-03
Type of information: Nomination
Compound:
Company: Quantum Genomics (France)
Therapeutic area: Cardiovascular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 3, 2016, Quantum Genomics announced the establishment of a U.S. Clinical Advisory Board of renowned cardiologists and cardiovascular researchers. The members will provide clinical and strategic guidance to the Company on the design of its hypertension clinical trial in the U.S. for lead product candidate QGC001, planned for 2017. Additionally, this newly-formed Clinical Advisory Board will work with the Scientific Advisory Board members to raise visibility of the Company’s novel class of centrally-acting drugs called Brain Aminopeptidase A Inhibitors (BAPAIs) for the treatment of high blood pressure and the prevention of related cardiovascular risks such as heart failure. The initial appointments to Quantum Genomics’ Clinical Advisory Board include:
Keith Ferdinand, MD — Professor of Medicine at the Tulane University School of Medicine;
Henry Black, MD — Adjunct Clinical Professor of Medicine and member of the Section of Cardiology at the New York University School of Medicine, New York;
Howard Dittrich, MD — Adjunct Professor of Medicine at the University of Iowa Carver College of Medicine and Chairman of the Board of Directors of the François M. Abboud Cardiovascular Research Center at the University of Iowa Carver College of Medicine.
Financial terms:
Latest news:
